Incorporating Precision Medicine into Oncology

Video

In Partnership With:

Terrill Jordan, LLM, JD, MAcc, discusses challenges regarding the utility of precision medicine in oncology.

Terrill Jordan, LLM, JD, president and chief executive officer, Regional Cancer Care Associates, discusses challenges regarding the utility of precision medicine in oncology.

There is a robust pipeline of drugs in development in oncology, explains Jordan. The number of agents that are poised to enter the market may complicate current treatment strategies.

Notably, precision medicine has helped individualize treatment for patients. Among the flood of new agents, physicians should consider patient-specific factors when choosing a treatment.

Precision medicine can be costly; however, it appears to be cost-effective in the long-term, concludes Jordan.

Related Videos
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
Somedeb Ball, MBBS, assistant professor, medicine, Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center
Phillip J. Koo, MD
Gabriella Smith, MD
Mikkael A. Sekeres, MD, MS
Francesco Di Meo, PhD
Ko Un “Clara” Park, MD
Naseema Gangat, MBBS
Erin Frances Cobain, MD
Pashtoon Murtaza Kasi, MD, MS